Julia Prabucka-Marciniak

Julia Prabucka-Marciniak

Auto-generated profile, based on publicly available information

Julia Prabucka-Marciniak

Praski Hospital, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in The Cardiothoracic Surgeon
Verified
Journal Article
Open access
PDF file
ESEdyta Szymańska
Edyta Szymańska
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
Background: Tranexamic acid (TXA) is commonly utilized across multiple medical fields. This review evaluates the efficacy of its topical administration in cardiac surgery. Main body of the A comprehensive search of the PubMed database has been conducted using the keywords “tranexamic acid local cardiac surgery” and “tranexamic acid topical cardiac surgery.” In addition to PubMed, other relevant sources were reviewed, resulting in the selection of 23 meta-analyses, systematic reviews, and randomized controlled trials. This review evaluates the efficacy of topical TXA compared to intravenous (IV) TXA alone, saline, and the combination of IV and topical TXA in adult patients undergoing cardiac surgery. Results: In comparisons with placebo, topical TXA reduced postoperative blood loss; however, its impact on transfusion rates remains unclear. When compared to IV TXA, topical administration demonstrated similar efficacy in minimizing blood loss and was associated with a lower risk of postoperative seizures. However, topical TXA was linked to a higher incidence of blood transfusions. Studies comparing combined topical and IV TXA with IV administration alone reported no significant differences in blood loss or transfusion rates. Variability in patient populations and study protocols limited the ability to make direct comparisons. In off-pump coronary artery bypass grafting (OPCAB), topical TXA may reduce postoperative blood loss, but no studies have directly compared its effectiveness to IV TXA in this context. Furthermore, graft patency, a critical measure for assessing the safety of antifibrinolytic agents, was not evaluated. Conclusions: Topical TXA has shown promising results in reducing blood loss after cardiac procedures. Nevertheless, further research is needed due to the significant heterogeneity and limited sample sizes in existing studies. Current clinical guidelines indicate that topical TXA is less effective than IV TXA for reducing transfusion requirements, suggesting that topical TXA should not be administered routinely in every case (Class III, Level B). Topical TXA may be considered when standard hemostatic methods are insufficient (Class II, Level B). Furthermore, guidelines recommend the use of topical TXA after cardiopulmonary bypass (CBP) to decrease postoperative drainage and transfusion requirements (Class IIA, Level B-R).

30 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ESEdyta Szymańska
Edyta Szymańska
AMAdrianna Maria Mikołajczyk
Adrianna Maria Mikołajczyk
PPPatryk Pustuła
Patryk Pustuła
APAnna Maria Pietrzak
Anna Maria Pietrzak
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
HFHanna Eve Feder
Hanna Eve Feder
Background: Acute ischemic stroke (AIS) in the pediatric population is a rare condition. Despite its severe outcomes—including long-term neurological deficits and mortality— diagnosis of pediatric AIS is often delayed. In contrast to adult AIS, evidence-based guidelines for the pediatric population are limited, primarily due to the absence of data from multicenter randomized clinical trials. Aim: This review aims to present a comprehensive overview of the treatment methods of AIS in children, focusing on thrombolysis, mechanical thrombectomy, and supportive neuroprotective strategies. Material and Methods: An in-depth literature review was performed using PubMed, ScienceDirect, and Google Scholar, including keywords such as: “pediatric acute ischemic stroke”, “PAIS”, “acute ischemic stroke in children”, “acute ischemic stroke management”, “tenecteplase”, “thrombolysis in children” Results: Intravenous thrombolysis with alteplase (0.9 mg/kg) may be considered in children ≥2 years of age within 4.5 hours of symptom onset, although data are still limited due to poor patient enrollment in the Thrombolysis in Pediatric Stroke Study (TIPS). Mechanical thrombectomy may be effective, even beyond the 6-hour window, particularly in cases involving large-vessel occlusion. Neuroprotective measures—such as glucose, temperature, and blood pressure control—may contribute to improved outcomes. For secondary prevention, antiplatelet or anticoagulant therapy is recommended. Conclusions: Management of AIS in children still relies on extrapolated adult data. There is an urgent need for pediatric-specific clinical trials to establish evidence-based treatment protocols and guidelines. In the meantime, early diagnosis, reperfusion strategies, and supportive neuroprotective measures appear to be critical.

16 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
KKKacper Kmieć
Kacper Kmieć
JPJakub Pysiewicz
Jakub Pysiewicz
ESEdyta Szymańska
Edyta Szymańska
Background: Hematopoietic stem cell transplantation (HSCT) has expanded its scope as a curative therapy for a wide range of severe pediatric diseases. However, its efficacy is frequently challenged by graft-versus-host disease (GVHD), a significant and potentially fatal complication. This is particularly relevant in the pediatric population, where unique immunological and physiological factors contribute to a distinct disease course. Objective: This narrative review synthesizes the current evidence base on the treatment and management of GVHD in pediatric patients. It aims to provide a critical appraisal of the unique immunological determinants, current prophylactic and treatment interventions, and the long-term morbidities and clinical needs for this specific field. Methods: A comprehensive systematic search of databases, including PubMed, Embase, and the Cochrane Library, was conducted to identify relevant literature. Articles were selected based on inclusion criteria focusing on GVHD management in patients aged 18 or younger, while excluding non-peer-reviewed articles and case reports. Data on study design, patient populations, treatment regimens, and key outcomes were extracted and synthesized. Summary: The pathogenesis of acute GVHD (aGVHD) is described by the classic three-phase model, beginning with host tissue damage, followed by donor T-cell activation, and culminating in targeted organ destruction, particularly in the skin, liver, and gastrointestinal tract. Diagnostic methods have evolved from clinical and histological assessments to include advanced biomarker-driven approaches, such as the MAGIC algorithm, which provides more precise prognostic risk stratification. Current prophylaxis strategies primarily involve calcineurin inhibitors in combination with methotrexate or mycophenolate mofetil. Novel agents like ruxolitinib and vedolizumab are emerging as promising therapeutic tools for both prophylaxis and the treatment of steroid-refractory disease. Despite these advancements, significant clinical gaps persist, as many established guidelines for GVHD management are not tailored to the pediatric population. The evident age-related disparity in GVHD risk highlights the critical need for pediatric-specific research. Conclusion: While substantial progress has been made in understanding and treating GVHD, there is a clear and urgent need for further research focused on pediatric-specific protocols. Continued efforts to validate existing therapies in pediatric cohorts, explore novel agents, and leverage biomarkers are essential to improve outcomes and the quality of life for young patients undergoing HSCT.

31 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
Soft tissue sarcomas (STS) of the head and neck are rare and histologically diverse malignancies that present unique diagnostic and therapeutic challenges due to their proximity to critical anatomical structures. They originate from various tissues, including fat, muscle, nerves, blood vessels, and others. Although they account for a small proportion of all STS, their management requires individualized care within experienced sarcoma centres. While surgery and radiotherapy remain the primary modalities, newer systemic and targeted strategies are increasingly being incorporated into clinical practice. In this review we summarise current state of knowledge related to the diagnosis, staging, and treatment of head and neck STS in adults. We also discuss evolving systemic and targeted therapies with potential relevance to clinical oncology practice.

3 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MDMateusz Dembiński
Mateusz Dembiński
MBMichał Bereza
Michał Bereza
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
JPJakub Pysiewicz
Jakub Pysiewicz
HRHubert Rycyk
Hubert Rycyk
Vascular diseases are a major source of global morbidity and mortality, often requiring surgical intervention, but the long-term outcomes are frequently compromised by complications like graft failure and restenosis. Since traditional imaging methods often detect these issues only at an advanced stage, there is a critical need for more precise and earlier risk prediction tools. This comprehensive narrative review synthesizes existing literature on the predictive value of circulating and tissue-based biomarkers for these adverse outcomes. The study systematically examined major electronic databases including PubMed, Scopus, and Web of Science, utilizing keywords related to vascular surgery, outcomes (e.g., graft failure, restenosis), and biomarkers. The identified biomarkers were categorized into four principal groups: inflammatory, lipid-related, genetic, and novel/emerging markers. The review found that elevated levels of inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and various interleukins (IL-6, IL-1β, TNF-α, IL-18, IL-33)—are strongly associated with an increased risk of graft failure and restenosis. Conversely, anti-inflammatory interleukins like IL-10 and IL-19 were found to correlate with a reduced risk. Furthermore, an unfavorable lipid profile (high LDL, low HDL, or an elevated LDL/HDL ratio) was consistently linked to a higher incidence of these complications. The review also highlights the promising potential of genetic markers, such as specific single nucleotide polymorphisms (SNPs), and novel biomarkers like non-coding RNAs in developing personalized treatment strategies. The findings suggest that incorporating biomarker panels into routine clinical practice could significantly enhance preoperative risk stratification, enabling tailored perioperative therapy and more effective postoperative surveillance. By allowing for the early detection of biological evidence of graft compromise, this precision-medicine model has the potential to substantially improve long-term patient outcomes in vascular surgery.

17 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKacper Kmieć
Kacper Kmieć
ESEdyta Szymańska
Edyta Szymańska
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
JPJakub Pysiewicz
Jakub Pysiewicz
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for a variety of pediatric hematologic and non-malignant disorders, yet chronic graft-versus-host disease (cGVHD) remains the primary cause of long-term non-relapse morbidity and mortality. The incidence of cGVHD in children has been increasing, a trend associated with the expanded use of peripheral blood stem cells and unrelated donors. Despite generally lower rates than adults, cGVHD remains a significant and growing clinical problem with profound long-term implications for pediatric survivors, who have a much greater life expectancy. Objective: This review aims to provide a focused and much-needed overview of cGVHD in children. Specifically, it delineates the unique epidemiological, pathobiological, and clinical characteristics that distinguish the disease in this population, including immunological distinctions, diagnostic challenges, and special considerations for long-term effects. This report highlights the pressing questions in treatment and research, addressing the historical lack of specialized data and emphasizing the principle that "children are not small adults" in the context of this complex condition. Methods: This review was conducted by systematically analyzing and synthesizing peer-reviewed articles, clinical guidelines, and consensus statements related to pediatric cGVHD. A comprehensive literature search was performed across databases including PubMed, Scopus, and Embase using a combination of keywords such as "pediatric," "chronic GvHD," "children," "hematopoietic stem cell transplantation," "management," "diagnosis," and "long-term effects." Summary: The lower incidence and severity of cGVHD in children are attributable to distinct biological factors, including superior thymic function and a greater use of bone marrow or cord blood grafts. However, diagnostic challenges persist due to non-specific symptoms and the limitations of adult-derived criteria. The profound and age-specific impacts of the disease and its treatments on growth, neurocognitive development, and infectious risk underscore the disproportionate long-term burden on pediatric survivors. The review discusses therapeutic strategies that prioritize steroid-sparing regimens and the integration of novel targeted inhibitors and cellular therapies. Conclusion: A paradigm shift is necessary, advocating for dedicated pediatric research, age-adapted diagnostic tools, and a multidisciplinary, holistic approach to long-term survivorship care to optimize the functional status and quality of life for children with cGVHD.